表紙
市場調查報告書
商品編碼
926277

循環腫瘤細胞 (CTC) :分離 & 檢測的專利形勢

Circulating Tumor Cells: Isolation & Detection Patent Landscape

出版日期: | 出版商: KnowMade | 英文 PDF >160 Slides, Excel file >5,500 Patents | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供循環腫瘤細胞 (CTC)的分離 & 檢測相關專利形勢的相關調查,IP趨勢,每應用的專利市場區隔,主要專利受讓人的排行榜,主要企業的IP地位和專利組合的優勢,主要的專利和其詳細,及主要企業簡介等,分析。

簡介

調查手法

提及的主要受讓人

摘要整理

專利形勢概要

  • 專利公開的時間發展
  • 專利申請國
  • 時間發展:專利申請各國
  • 專利申請最多排行榜
  • 主要企業的目前法律情形
  • 專利的法律上的情形
  • 主要的目前IP所有者的製圖
  • IP主要企業的專利活動
  • 主要的專利申請人的時間發展
  • 新興企業
  • 主要的IP合作
  • 主要的收購

主要的專利申請人的IP地位

  • 專利申請人的IP龍頭
  • 專利申請人的IP區塊可能性
  • 專利組合的強度目錄

主要的專利

  • 專利引用分析
  • 主要的專利家庭
  • EP專利相關主要異議
  • 失效的主要專利:2019年
  • 失效的主要專利:2020年
  • 失效的主要專利:2021年

專利市場區隔

  • 定義
  • 主要的受讓人:各技術
  • 主要的受讓人:各IP地位、技術
  • CTC分離的物理的特性
  • CTC分離的生物學的特性
  • CTC檢測、特性評估
  • CTC分離、檢測的其他方法
  • 醫療設備
  • CTC穩定化
  • IP

主要企業的簡介

結論

KNOWMADE

簡報

目錄
Product Code: KM20002

Report's Key Features

  • PDF with > 160 slides
  • Excel file > 5,500 patents
  • IP trends, including time-evolution of published patents, and countries of patent filings
  • Patents' legal status
  • Ranking of main patent assignees
  • Key players' IP position and relative strength of their patent portfolios
  • Summary of the IP related to the physical isolation: size, deformability, electrical charges or density.
  • Summary of the IP related to the biological isolation: positive or negative enrichment.
  • Summary of the IP related to the CTC detection: nucleic acid, protein or functional assay.
  • Analysis of patent litigations and review of key patents.
  • Excel database containing all patents analyzed in the report, including biological and physical isolation and detection segmentations

CTC isolation and detection, an essential step in cancer prognostic and personalized treatment

Cancer is the second leading cause of death worldwide and was responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer (source: WHO). One defining feature of cancer is the rapid creation of abnormal cells that grow beyond their usual boundaries, and which can then invade adjoining parts of the body and spread to other organs. The latter process is referred to as metastasizing. Metastasis is a major cause of death from cancer. Preventing or detecting metastasis outbreak has therefore become a main issue in cancer prognostic (to predict the development and the outcome of the cancer) and in personalized treatment. The discovery of circulating tumor cells (CTC) was a milestone in understanding tumoral progression, and their presence in the blood enables a less invasive biopsy (liquid biopsy) which is beneficial for the patient. Then, the development of devices to intercept and analyze these rare cells steeply increased in the last 10 years, as did the number of companies supplying them (e.g. Menarini Silicon Biosystems, GPB Scientific, Gilupi, Epic Sciences). However, this development seems to be slower than in other sectors, like the free circulating DNA area, and certain key facts could explain this lower progression. First, CTC are hard to transport and store, because cell integrity is difficult to maintain. To counteract this issue, most companies develop instruments which can be directly sold to end users, but they are expensive and complex to manufacture. Then, the transfer from laboratories to clinical practice is full of obstacles, like the complexity of clinical trials or the difficulty in getting authorization from administrative bodies (e.g. the FDA). However, understanding of CTC and technology to isolate them are advancing quickly. Monitoring these rare cells as a prognostic tool among patients is an increasingly confirmed practice, as is the significance of fully characterizing a cell to enable personalized treatment. CTC isolation & detection interests big companies and start-ups alike, and it is crucial to understand the intellectual property position and strategy of these different players. Such knowledge can help detect business risks and opportunities, anticipate emerging technologies, and enable strategic decisions to strengthen one's market position.

The analysis of the time evolution of patent publications shows that CTC isolation and detection started to be investigated in the late 1990s with a first patent filed in 1995 by Dendreon (company acquired by San Power in 2017). Until 2009, there is a latent period, even if big pharmaceutical companies and some academics begin to take interest in CTC. From 2010 to 2016, an acceleration is observed with big newcomers (Nestlé, Samsung, Siemens or Hitachi Chemicals). In 2016-2017, publications stagnated despite the arrival of new players. The main patent assignees are US industrial players that develop an international intellectual property strategy. Europe and China are the main countries of protection, which appear to be strategic territories for these applicants.

Analysis by segment

CTC could be isolated and detected using various methods. Therefore, a technological segmentation was made in this IP landscape, as follows:

  • CTC isolation: Efficient enrichment of CTC can be achieved by approaches that exploit differences between tumor cells and blood cells, including the differential expression of cell surface proteins or distinct physical properties of the cells.
    • Physical isolation: Assays are based on CTC physical characteristics including size, deformability, density and electrical charge.
    • Biological isolation: It is protein-based methods which rely mainly on specific markers that are detected by antibodies or by other particles like aptamers. The sample can be enriched in desired cells (positive isolation) or depleted in unwanted cells (negative isolation).
  • CTC detection: Once CTC concentration is increased, for an unambiguous isolation of CTC, detection methods are necessary.
    • Nucleic Acid: DNA or RNA are identified by RT-PCR, FISH, etc.
    • Protein: Surface markers are detected by antibodies (anti-EpCam, Anti-Cytokeratin, etc.) and visualized by microscopy, FACS, etc.
    • Functional assays: EPISPOT or invasion assays.
  • Other technologies: Raman spectroscopy, surface acoustic waves or the use of virus or phagocytic cells, etc.
  • Medical devices: In vivo apparatus like an implantable device or apheresis.

For each segment, the patent publication timeline and the patent portfolios of main players were analyzed. If the technology results in a clinical trial, the corresponding patent, the clinical trial and the scientific publication are described.

Identifying the companies that have recently emerged in the IP landscape

Among the players that have filed patents related to CTC isolation and detection, over 60 newcomers were identified. These companies are established companies and startup firms developing their first products in the CTC area. These technologies are mainly related to CTC positive enrichment, size-based isolation or nucleic acid detection. Numerous IP newcomers are based in Asia and in the US while some are based in Europe. It is possible that one of these innovative companies could become one of the next healthcare unicorns that the big corporations will be tempted to acquire.

Key patent analysis

This IP study includes selection and description of key patents. The key patent analysis includes the legal state of the family for each of the main territories, the number of received citations, the review of the main claim(s), the description of interesting features about the innovation disclosures and relevant figures illustrating how the innovation works. The description also contains information about the fact that the patent family was involved in a patent litigation in the USA.

Moreover, the report also includes an Excel database with the >1,680 patents analyzed in this study. This useful patent database allows for multi-criteria searches and includes patent publication numbers, hyperlinks to the original documents, priority dates, titles, abstracts, patent assignees, each patent's current legal status and segmentation to which it belongs.

Companies mentioned in this report (non-exhaustive list)

ABBOTT, ABBVIE, ARKRAY, ASTELLAS, AVIVA BIOSCIENCES, BECTON DICKINSON, BIOCEPT, CELSEE, CREATV MICROTECH, CYTOGEN, CYTTEL BIOSCIENCES, DECIPHER BIOSCIENCE, EPIC SCIENCES, EUTROPICS PHARMACEUTICALS, GENCURIX, GENOBIO, GILUPI, GPB SCIENTIFIC, HITACHI CHEMICAL, ILLUMINA, JANSSEN DIAGNOSTICS, JUSBIO SCIENCES, KONICA MINOLTA, LUNG LIFE AI, MENARINI SILICON BIOSYSTEMS, NESTLE, RARECYTE, ROCHE, GENENTECH, SUMITOMO, SUREXAM, TOSOH

TABLE OF CONTENTS

INTRODUCTION

  • Definition of a circulating tumor cell
  • Scope of the report
  • Key features of the report
  • Objectives of the report

METHODOLOGY

  • Patent search, selection and analysis
  • Search strategy
  • Terminologies for patent analysis
  • Strength and blocking potential

MAIN ASSIGNEES MENTIONED

EXECUTIVE SUMMARY

PATENT LANDSCAPE OVERVIEW

  • Time evolution of patent publications
  • Countries of patent filings
  • Time evolution by country of filing
  • Ranking of most prolific patent applicants
  • Current legal status of the main players
  • Patent legal status of the corpus
  • Mapping of main current IP holders
  • Patenting activity of IP leading companies
  • Time evolution of main patent assignees
  • Newcomers
  • Main IP collaborations
  • Main acquisitions

IP POSITION OF MAIN PATENT APPLICANTS

  • IP leadership of patent applicants
  • IP blocking potential of patent applicants
  • Strength index of patent portfolios

KEY PATENTS

  • Patent citation analysis
  • Key patent families
  • Main oppositions on EP patents
  • Main granted patents expired or lapsed in 2019
  • Main granted patents that will expire in 2020
  • Main granted patents that will expire in 2021

PATENT SEGMENTATION

  • Definition
  • Main assignees by technology
  • Main assignees by IP position and technology
  • CTC isolation physical properties
  • CTC isolation biological properties
  • CTC detection and characterization
  • CTC isolation and detection Other methods
  • medical devices
  • CTC stabilization
  • IP

PROFILE OF KEY PLAYERS

CONCLUSION

KNOWMADE

PRESENTATION